Skip to main content
logo
Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
29.48
+0.62 (2.15%)
At close: Aug 14, 2026, 4:00 PM EDT
29.49
+0.01 (0.03%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Arcus Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
117247258117112383
Revenue Growth
-55.34%-4.26%120.51%4.46%-70.76%391.03%
Cost of Revenue
497523448340288257
Gross Profit
-380-276-190-223-176126
Selling, General & Admin
10611012011710472
Operating Expenses
10611012011710472
Operating Income
-486-386-310-340-28054
Interest Expense
-11-8-4-2-2-
Interest & Investment Income
37415241161
EBT Excluding Unusual Items
-460-353-262-301-26655
Asset Writedown
---20---
Pretax Income
-460-353-282-301-26655
Income Tax Expense
--1612
Net Income
-460-353-283-307-26753
Net Income to Common
-460-353-283-307-26753
Net Income Growth
------
Shares Outstanding (Basic)
11910790747269
Shares Outstanding (Diluted)
11910790747274
Shares Change
22.85%19.20%21.76%2.78%-2.70%35.04%
EPS (Basic)
-3.86-3.29-3.14-4.15-3.710.76
EPS (Diluted)
-3.86-3.29-3.14-4.15-3.710.71
EPS Growth
------
Free Cash Flow
-475-484-176-330432-282
Free Cash Flow Per Share
-3.99-4.51-1.95-4.466.00-3.81
Gross Margin
--111.74%-73.64%-190.60%-157.14%32.90%
Operating Margin
-415.39%-156.28%-120.15%-290.60%-250.00%14.10%
Profit Margin
-393.16%-142.91%-109.69%-262.39%-238.39%13.84%
Free Cash Flow Margin
-405.98%-195.95%-68.22%-282.05%385.71%-73.63%
EBITDA
-476-376-300-332-27458
EBITDA Margin
--152.23%-116.28%-283.76%-244.64%15.14%
D&A For EBITDA
101010864
EBIT
-486-386-310-340-28054
EBIT Margin
--156.28%-120.15%-290.60%-250.00%14.10%
Effective Tax Rate
-----3.64%
Revenue as Reported
117247258117112383
SEC Filings: 10-K · 10-Q